News Column

New Findings on Breast Cancer from University of Delhi Summarized (Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for...

July 7, 2014

New Findings on Breast Cancer from University of Delhi Summarized (Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy)

By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on Oncology is now available. According to news reporting from Delhi, India, by NewsRx journalists, research stated, "Noscapine (Nos), an orally available plant-derived antitussive alkaloid, is in phase II clinical trials for cancer chemotherapy. It has extensively been shown to inhibit tumor growth in nude mice bearing human xenografts of hematopoietic, breast, lung, ovarian, brain, and prostate origin."

The news correspondents obtained a quote from the research from the University of Delhi, "However, high tumor-suppressive Nos dosages encumber the development of oral controlled-release formulations because of a short biological half-life (< 2 h), poor absorption, low aqueous solubility, and extensive first-pass metabolism. Here, we present the design, fabrication, optimization, characterization, and biological evaluation of estrone-conjugated noscapine-loaded gelatin nanoparticles (Nos-ES-GN) for targeting estrogen-receptor-positive breast cancer MCF-7 cells. Gelatin nanoparticles (GN) were a uniformly compact size, stable at physiological pH, and showed a drug entrapment efficiency of 66.1 +/- 5.9 and 65.2 +/- 5.6% for Nos-GN and Nos-ES-GN, respectively. The secondary structure of gelatin nanocoacervates was predicted using circular dichroism and in-silico molecular modeling. Our data suggest that ethanol-fabricated GN retained the alpha-helical content of gelatin, whereas acetone favored the formation of random coils. The conjugation of estrone to Nos-GN did not affect the release rate of the drug, and both formulations followed first-order release kinetics with an initial burst, followed by a slow release. The IC50 value of Nos-ES-GN was 21.2 mu mol/l, which was similar to 50% lower than the free drug (43.3 mu mol/l), suggesting targeted drug delivery. Our cell uptake study carried out in an estrogen-receptor-positive (MCF-7) and negative (MDA-MB-231) cancer cell lines showed greater accumulation of Nos-ES-GN in MCF-7 cells instead of MDA-MB-231 cells."

According to the news reporters, the research concluded: "Our data indicated that estrone-conjugated nanoparticles may potentially be used for targeting breast cancer cells."

For more information on this research see: Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy. Anti-Cancer Drugs, 2014;25(6):704-716. Anti-Cancer Drugs can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins -; Anti-Cancer Drugs -

Our news journalists report that additional information may be obtained by contacting J. Madan, University of Delhi, Dr BR Ambedkar Center Biomed Res, Delhi 110007, India. Additional authors for this research include S.R. Gundala, Y. Kasetti, P.V. Bharatam, R. Aneja, A. Katyal and U.K. Jain (see also Oncology).

Keywords for this news article include: Asia, Delhi, Gelatin, Therapy, Oncology, Nanoparticle, Breast Cancer, Nanotechnology, Scleroproteins, Women's Health, Steroid Receptors, Estrogen Receptors, DNA-Binding Proteins, Emerging Technologies, Transcription Factors

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters